Drug Profile
ABBV 553
Alternative Names: ABBV-553Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Inventiva Pharma
- Developer AbbVie; Inventiva Pharma
- Class Antipsoriatics; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Psoriasis(In the elderly, In adults) in USA (PO)
- 02 Nov 2017 AbbVie terminates a phase I trial in Psoriasis (In adults, In the elderly) in USA due to safety reason (PO) (NCT03145948)
- 25 Sep 2017 Development discontinued for psoriasis during 2017